The DOI matches its Crossref record; 183 of the 183 references it cites were found in a registry or an index.
Precision treatment in advanced hepatocellular carcinoma
Open accessAbstract
The past decade has witnessed significant advances in the systemic treatment of advanced hepatocellular carcinoma (HCC). Nevertheless, the newly developed treatment strategies have not achieved universal success and HCC patients frequently exhibit therapeutic resistance to these therapies. Precision treatment represents a paradigm shift in cancer treatment in recent years. This approach utilizes the unique molecular characteristics of individual patient to personalize treatment modalities, aiming to maximize therapeutic efficacy while minimizing side effects. Although precision treatment has shown significant success in multiple cancer types, its application in HCC remains in its infancy. In this review, we discuss key aspects of precision treatment in HCC, including therapeutic biomarkers, molecular classifications, and the heterogeneity of the tumor microenvironment. We also propose future directions, ranging from revolutionizing current treatment methodologies to personalizing therapy through functional assays, which will accelerate the next phase of advancements in this area.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Self-citationCheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Kudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30207-1 · Cited by 5,497
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
The distribution of secondary growths in cancer of the breast.
Paget, S. (1889) · The Lancet · doi:10.1016/s0140-6736(00)49915-0 · Cited by 5,277
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
Self-citationEl-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y.-H., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Breder, V., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32453-9 · Cited by 3,653
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
Marabelle, A., Fakih, M., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H. C., Kindler, H. L., Lopez-Martin, J. A., Miller, W. H., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30445-9 · Cited by 2,552
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma
Ally, A., Balasundaram, M., Carlsen, R., Chuah, E., Clarke, A., Dhalla, N., Holt, R. A., Jones, S. J. M., Lee, D., Ma, Y., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.046 · Cited by 2,490
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488
Zhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30351-6 · Cited by 2,479
Self-citationVogel, A., Meyer, T., Sapisochin, G., Salem, R., & Saborowski, A. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01200-4 · Cited by 2,427
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
Abou-Alfa, G. K., Meyer, T., Cheng, A.-L., El-Khoueiry, A. B., Rimassa, L., Ryoo, B.-Y., Cicin, I., Merle, P., Chen, Y., Park, J.-W., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1717002 · Cited by 2,344
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernández-Mateos, J., Khan, K., Lampis, A., Eason, K., Huntingford, I., Burke, R., et al. (2018) · Science · doi:10.1126/science.aao2774 · Cited by 2,096
Molecular therapies and precision medicine for hepatocellular carcinoma
Llovet, J. M., Montal, R., Sia, D., & Finn, R. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0073-4 · Cited by 1,938
Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention
Huang, D. Q., El-Serag, H. B., & Loomba, R. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00381-6 · Cited by 1,855
Schulze, K., Imbeaud, S., Letouzé, E., Alexandrov, L. B., Calderaro, J., Rebouissou, S., Couchy, G., Meiller, C., Shinde, J., Soysouvanh, F., et al. (2015) · Nature Genetics · doi:10.1038/ng.3252 · Cited by 1,803
Finn, R. S., Ryoo, B.-Y., Merle, P., Kudo, M., Bouattour, M., Lim, H. Y., Breder, V., Edeline, J., Chao, Y., Ogasawara, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01307 · Cited by 1,789
Self-citationCheng, A.-L., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Lim, H. Y., Kudo, M., Breder, V., Merle, P., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.11.030 · Cited by 1,743
Self-citationZhu, A. X., Kang, Y.-K., Yen, C.-J., Finn, R. S., Galle, P. R., Llovet, J. M., Assenat, E., Brandi, G., Pracht, M., Lim, H. Y., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30937-9 · Cited by 1,662
Self-citationTremelimumab plus durvalumab in unresectable hepatocellular carcinoma
Abou-Alfa, G. K., Lau, G., Kudo, M., Chan, S. L., Kelley, R. K., Furuse, J., Sukeepaisarnjaroen, W., Kang, Y.-K., Van Dao, T., De Toni, E. N., et al. (2022) · NEJM Evidence · doi:10.1056/evidoa2100070 · Cited by 1,576
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
Doroshow, D. B., Bhalla, S., Beasley, M. B., Sholl, L. M., Kerr, K. M., Gnjatic, S., Wistuba, I. I., Rimm, D. L., Tsao, M. S., & Hirsch, F. R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00473-5 · Cited by 1,575
Gut microbiome–mediated bile acid metabolism regulates liver cancer via NKT cells
Ma, C., Han, M., Heinrich, B., Fu, Q., Zhang, Q., Sandhu, M., Agdashian, D., Terabe, M., Berzofsky, J. A., Fako, V., et al. (2018) · Science · doi:10.1126/science.aan5931 · Cited by 1,508
Human primary liver cancer–derived organoid cultures for disease modeling and drug screening
Broutier, L., Mastrogiovanni, G., Verstegen, M. M., Francies, H. E., Gavarró, L. M., Bradshaw, C. R., Allen, G. E., Arnes-Benito, R., Sidorova, O., Gaspersz, M. P., et al. (2017) · Nature Medicine · doi:10.1038/nm.4438 · Cited by 1,471
Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer
Rojas, L. A., Sethna, Z., Soares, K. C., Olcese, C., Pang, N., Patterson, E., Lihm, J., Ceglia, N., Guasp, P., Chu, A., et al. (2023) · Nature · doi:10.1038/s41586-023-06063-y · Cited by 1,432
Pan-cancer single-cell landscape of tumor-infiltrating T cells
Zheng, L., Qin, S., Si, W., Wang, A., Xing, B., Gao, R., Ren, X., Wang, L., Wu, X., Zhang, J., et al. (2021) · Science · doi:10.1126/science.abe6474 · Cited by 1,402
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Pfister, D., Núñez, N. G., Pinyol, R., Govaere, O., Pinter, M., Szydlowska, M., Gupta, R., Qiu, M., Deczkowska, A., Weiner, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03362-0 · Cited by 1,294
Yau, T., Kang, Y.-K., Kim, T.-Y., El-Khoueiry, A. B., Santoro, A., Sangro, B., Melero, I., Kudo, M., Hou, M.-M., Matilla, A., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.4564 · Cited by 1,273
Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets
Boyault, S., Rickman, D. S., de Reyniès, A., Balabaud, C., Rebouissou, S., Jeannot, E., Hérault, A., Saric, J., Belghiti, J., Franco, D., et al. (2007) · Hepatology · doi:10.1002/hep.21467 · Cited by 1,258
Hoshida, Y., Nijman, S. M. B., Kobayashi, M., Chan, J. A., Brunet, J.-P., Chiang, D. Y., Villanueva, A., Newell, P., Ikeda, K., Hashimoto, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1089 · Cited by 1,238
Unlocking the potential of antibody–drug conjugates for cancer therapy
Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00470-8 · Cited by 1,150
Ren, Z., Xu, J., Bai, Y., Xu, A., Cang, S., Du, C., Li, Q., Lu, Y., Chen, Y., Guo, Y., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00252-7 · Cited by 1,124
Self-citationYau, T., Park, J.-W., Finn, R. S., Cheng, A.-L., Mathurin, P., Edeline, J., Kudo, M., Harding, J. J., Merle, P., Rosmorduc, O., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00604-5 · Cited by 1,106
Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma
Gao, Q., Zhu, H., Dong, L., Shi, W., Chen, R., Song, Z., Huang, C., Li, J., Dong, X., Zhou, Y., et al. (2019) · Cell · doi:10.1016/j.cell.2019.08.052 · Cited by 1,096
Self-citationBuonacera, A., Stancanelli, B., Colaci, M., & Malatino, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073636 · Cited by 1,083
McGrail, D. J., Pilié, P. G., Rashid, N. U., Voorwerk, L., Slagter, M., Kok, M., Jonasch, E., Khasraw, M., Heimberger, A. B., Lim, B., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.02.006 · Cited by 1,032
Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
Sia, D., Jiao, Y., Martinez-Quetglas, I., Kuchuk, O., Villacorta-Martin, C., Castro de Moura, M., Putra, J., Camprecios, G., Bassaganyas, L., Akers, N., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.06.007 · Cited by 976
Systemic Immunity Is Required for Effective Cancer Immunotherapy
Spitzer, M. H., Carmi, Y., Reticker-Flynn, N. E., Kwek, S. S., Madhireddy, D., Martins, M. M., Gherardini, P. F., Prestwood, T. R., Chabon, J., Bendall, S. C., et al. (2017) · Cell · doi:10.1016/j.cell.2016.12.022 · Cited by 963
Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma
Chinese Human Proteome Project (CNHPP) Consortium, Jiang, Y., Sun, A., Zhao, Y., Ying, W., Sun, H., Yang, X., Xing, B., Sun, W., Ren, L., et al. (2019) · Nature · doi:10.1038/s41586-019-0987-8 · Cited by 947
Self-citationLiver tumour immune microenvironment subtypes and neutrophil heterogeneity
Xue, R., Zhang, Q., Cao, Q., Kong, R., Xiang, X., Liu, H., Feng, M., Wang, F., Cheng, J., Li, Z., et al. (2022) · Nature · doi:10.1038/s41586-022-05400-x · Cited by 935
mRNA vaccine for cancer immunotherapy
Miao, L., Zhang, Y., & Huang, L. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01335-5 · Cited by 934
Yau, T. (., Park, J. W. (.-W., Finn, R. S. (. S. )., Cheng, A. L. (.-L., Mathurin, P., Edeline, J., Kudo, M. (., Harding, J. J., Merle, P., Rosmorduc, O., et al. (2022) · Deposito Adademico Digital Universidad De Navarra (University of Navarra) · Cited by 934
Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling
Lee, J.-S., Chu, I.-S., Heo, J., Calvisi, D. F., Sun, Z., Roskams, T., Durnez, A., Demetris, A. J., & Thorgeirsson, S. S. (2004) · Hepatology · doi:10.1002/hep.20375 · Cited by 922
Ruiz de Galarreta, M., Bresnahan, E., Molina-Sánchez, P., Lindblad, K. E., Maier, B., Sia, D., Puigvehi, M., Miguela, V., Casanova-Acebes, M., Dhainaut, M., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0074 · Cited by 912
Wang, Z., Aguilar, E. G., Luna, J. I., Dunai, C., Khuat, L. T., Le, C. T., Mirsoian, A., Minnar, C. M., Stoffel, K. M., Sturgill, I. R., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0221-5 · Cited by 865
Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors
Sha, D., Jin, Z., Budczies, J., Kluck, K., Stenzinger, A., & Sinicrope, F. A. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0522 · Cited by 859
Turning cold tumors into hot tumors by improving T-cell infiltration
Liu, Y.-T., & Sun, Z.-J. (2021) · Theranostics · doi:10.7150/thno.58390 · Cited by 827
Mapping information-rich genotype-phenotype landscapes with genome-scale Perturb-seq
Replogle, J. M., Saunders, R. A., Pogson, A. N., Hussmann, J. A., Lenail, A., Guna, A., Mascibroda, L., Wagner, E. J., Adelman, K., Lithwick-Yanai, G., et al. (2022) · Cell · doi:10.1016/j.cell.2022.05.013 · Cited by 795
Peripheral T cell expansion predicts tumour infiltration and clinical response
Wu, T. D., Madireddi, S., de Almeida, P. E., Banchereau, R., Chen, Y.-J. J., Chitre, A. S., Chiang, E. Y., Iftikhar, H., O’Gorman, W. E., Au-Yeung, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2056-8 · Cited by 770
Qin, S., Chan, S. L., Gu, S., Bai, Y., Ren, Z., Lin, X., Chen, Z., Jia, W., Jin, Y., Guo, Y., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00961-3 · Cited by 746
Self-citationLiu, Y., Xun, Z., Ma, K., Liang, S., Li, X., Zhou, S., Sun, L., Liu, Y., Du, Y., Guo, X., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.01.011 · Cited by 735
Self-citationEvolving therapeutic landscape of advanced hepatocellular carcinoma
Yang, C., Zhang, H., Zhang, L., Zhu, A. X., Bernards, R., Qin, W., & Wang, C. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00704-9 · Cited by 727
Self-citationFocal Gains of VEGFA and Molecular Classification of Hepatocellular Carcinoma
Chiang, D. Y., Villanueva, A., Hoshida, Y., Peix, J., Newell, P., Minguez, B., LeBlanc, A. C., Donovan, D. J., Thung, S. N., Solé, M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0742 · Cited by 719
Obesity and Cancer: A Current Overview of Epidemiology, Pathogenesis, Outcomes, and Management
Pati, S., Irfan, W., Jameel, A., Ahmed, S., & Shahid, R. K. (2023) · Cancers · doi:10.3390/cancers15020485 · Cited by 677
McQuade, J. L., Daniel, C. R., Hess, K. R., Mak, C., Wang, D. Y., Rai, R. R., Park, J. J., Haydu, L. E., Spencer, C., Wongchenko, M., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30078-0 · Cited by 664
Zhu, A. X., Abbas, A. R., de Galarreta, M. R., Guan, Y., Lu, S., Koeppen, H., Zhang, W., Hsu, C.-H., He, A. R., Ryoo, B.-Y., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01868-2 · Cited by 652
Self-citationThe Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
Petitprez, F., Meylan, M., de Reyniès, A., Sautès-Fridman, C., & Fridman, W. H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00784 · Cited by 602
Molecular and histological correlations in liver cancer
Calderaro, J., Ziol, M., Paradis, V., & Zucman-Rossi, J. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.06.001 · Cited by 590
Bruix, J., Cheng, A.-L., Meinhardt, G., Nakajima, K., De Sanctis, Y., & Llovet, J. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.06.026 · Cited by 562
Zheng, Y., Wang, T., Tu, X., Huang, Y., Zhang, H., Tan, D., Jiang, W., Cai, S., Zhao, P., Song, R., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0650-9 · Cited by 550
Weeber, F., van de Wetering, M., Hoogstraat, M., Dijkstra, K. K., Krijgsman, O., Kuilman, T., Gadellaa-van Hooijdonk, C. G. M., van der Velden, D. L., Peeper, D. S., Cuppen, E. P. J. G., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1516689112 · Cited by 482
Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)
Zhou, J., Sun, H., Wang, Z., Cong, W., Zeng, M., Zhou, W., Bie, P., Liu, L., Wen, T., Kuang, M., et al. (2023) · Liver Cancer · doi:10.1159/000530495 · Cited by 477
Self-citationMagen, A., Hamon, P., Fiaschi, N., Soong, B. Y., Park, M. D., Mattiuz, R., Humblin, E., Troncoso, L., D’souza, D., Dawson, T., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02345-0 · Cited by 429
A neutrophil response linked to tumor control in immunotherapy
Gungabeesoon, J., Gort-Freitas, N. A., Kiss, M., Bolli, E., Messemaker, M., Siwicki, M., Hicham, M., Bill, R., Koch, P., Cianciaruso, C., et al. (2023) · Cell · doi:10.1016/j.cell.2023.02.032 · Cited by 412
Qin, S., Bi, F., Gu, S., Bai, Y., Chen, Z., Wang, Z., Ying, J., Lu, Y., Meng, Z., Pan, H., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00163 · Cited by 409
Bardia, A., Messersmith, W. A., Kio, E. A., Berlin, J. D., Vahdat, L., Masters, G. A., Moroose, R., Santin, A. D., Kalinsky, K., Picozzi, V., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.03.005 · Cited by 400
Shen, Q., Fan, J., Yang, X.-R., Tan, Y., Zhao, W., Xu, Y., Wang, N., Niu, Y., Wu, Z., Zhou, J., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70233-4 · Cited by 394
Self-citationRoles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
Zhang, H., Liu, L., Liu, J., Dang, P., Hu, S., Yuan, W., Sun, Z., Liu, Y., & Wang, C. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01725-x · Cited by 389
Self-citationRen, F., Ding, X., Zheng, M., Korzinkin, M., Cai, X., Zhu, W., Mantsyzov, A., Aliper, A., Aladinskiy, V., Cao, Z., et al. (2023) · Chemical Science · doi:10.1039/d2sc05709c · Cited by 365
Ho, W. J., Zhu, Q., Durham, J., Popovic, A., Xavier, S., Leatherman, J., Mohan, A., Mo, G., Zhang, S., Gross, N., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00234-4 · Cited by 360
Self-citationNonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment
Llovet, J. M., Willoughby, C. E., Singal, A. G., Greten, T. F., Heikenwälder, M., El-Serag, H. B., Finn, R. S., & Friedman, S. L. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00754-7 · Cited by 354
Tumor organoids: Opportunities and challenges to guide precision medicine
Veninga, V., & Voest, E. E. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.07.020 · Cited by 339
Kichenadasse, G., Miners, J. O., Mangoni, A. A., Rowland, A., Hopkins, A. M., & Sorich, M. J. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.5241 · Cited by 339
Pinyol, R., Montal, R., Bassaganyas, L., Sia, D., Takayama, T., Chau, G.-Y., Mazzaferro, V., Roayaie, S., Lee, H. C., Kokudo, N., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-316408 · Cited by 326
Scheiner, B., Pomej, K., Kirstein, M. M., Hucke, F., Finkelmeier, F., Waidmann, O., Himmelsbach, V., Schulze, K., von Felden, J., Fründt, T. W., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.09.035 · Cited by 303
Mao, J., Wang, D., Long, J., Yang, X., Lin, J., Song, Y., Xie, F., Xun, Z., Wang, Y., Wang, Y., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003334 · Cited by 275
Self-citationKim, R. D., Sarker, D., Meyer, T., Yau, T., Macarulla, T., Park, J.-W., Choo, S. P., Hollebecque, A., Sung, M. W., Lim, H.-Y., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0555 · Cited by 262
Self-citationInflamed and non-inflamed classes of HCC: a revised immunogenomic classification
Montironi, C., Castet, F., Haber, P. K., Pinyol, R., Torres-Martin, M., Torrens, L., Mesropian, A., Wang, H., Puigvehi, M., Maeda, M., et al. (2023) · Gut · doi:10.1136/gutjnl-2021-325918 · Cited by 253
Immune Exclusion-Wnt/CTNNB1 Class Predicts Resistance to Immunotherapies in HCC
Pinyol, R., Sia, D., & Llovet, J. M. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3778 · Cited by 249
Wu, L., Yan, J., Bai, Y., Chen, F., Zou, X., Xu, J., Huang, A., Hou, L., Zhong, Y., Jing, Z., et al. (2023) · Cell Research · doi:10.1038/s41422-023-00831-1 · Cited by 239
Self-citationPalmer, C. D., Rappaport, A. R., Davis, M. J., Hart, M. G., Scallan, C. D., Hong, S.-J., Gitlin, L., Kraemer, L. D., Kounlavouth, S., Yang, A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01937-6 · Cited by 236
Awad, M. M., Govindan, R., Balogh, K. N., Spigel, D. R., Garon, E. B., Bushway, M. E., Poran, A., Sheen, J. H., Kohler, V., Esaulova, E., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.08.003 · Cited by 234
Establishment of Patient-Derived Organoids and Drug Screening for Biliary Tract Carcinoma
Saito, Y., Muramatsu, T., Kanai, Y., Ojima, H., Sukeda, A., Hiraoka, N., Arai, E., Sugiyama, Y., Matsuzaki, J., Uchida, R., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.03.088 · Cited by 230
Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update
Gauthier, A., & Ho, M. (2013) · Hepatology Research · doi:10.1111/j.1872-034x.2012.01113.x · Cited by 222
Targeting FGFR4 Inhibits Hepatocellular Carcinoma in Preclinical Mouse Models
French, D. M., Lin, B. C., Wang, M., Adams, C., Shek, T., Hötzel, K., Bolon, B., Ferrando, R., Blackmore, C., Schroeder, K., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036713 · Cited by 216
Human primary liver cancer organoids reveal intratumor and interpatient drug response heterogeneity
Li, L., Knutsdottir, H., Hui, K., Weiss, M. J., He, J., Philosophe, B., Cameron, A. M., Wolfgang, C. L., Pawlik, T. M., Ghiaur, G., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.121490 · Cited by 215
Cell transcriptomic atlas of the non-human primate Macaca fascicularis
Han, L., Wei, X., Liu, C., Volpe, G., Zhuang, Z., Zou, X., Wang, Z., Pan, T., Yuan, Y., Zhang, X., et al. (2022) · Nature · doi:10.1038/s41586-022-04587-3 · Cited by 209
Self-citationA Pharmacogenomic Landscape in Human Liver Cancers
Qiu, Z., Li, H., Zhang, Z., Zhu, Z., He, S., Wang, X., Wang, P., Qin, J., Zhuang, L., Wang, W., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.07.001 · Cited by 203
Self-citationBiomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma
Teufel, M., Seidel, H., Köchert, K., Meinhardt, G., Finn, R. S., Llovet, J. M., & Bruix, J. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.01.261 · Cited by 202
Antibody–drug conjugates: in search of partners of choice
Fuentes-Antrás, J., Genta, S., Vijenthira, A., & Siu, L. L. (2023) · Trends in Cancer · doi:10.1016/j.trecan.2023.01.003 · Cited by 201
Tumor-associated macrophages trigger MAIT cell dysfunction at the HCC invasive margin
Ruf, B., Bruhns, M., Babaei, S., Kedei, N., Ma, L., Revsine, M., Benmebarek, M.-R., Ma, C., Heinrich, B., Subramanyam, V., et al. (2023) · Cell · doi:10.1016/j.cell.2023.07.026 · Cited by 197
Shi, J.-Y., Wang, X., Ding, G.-Y., Dong, Z., Han, J., Guan, Z., Ma, L.-J., Zheng, Y., Zhang, L., Yu, G.-Z., et al. (2021) · Gut · doi:10.1136/gutjnl-2020-320930 · Cited by 191
Self-citationMetabolism‐associated molecular classification of hepatocellular carcinoma
Yang, C., Huang, X., Liu, Z., Qin, W., & Wang, C. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12639 · Cited by 189
Self-citationThe next horizon in precision oncology: Proteogenomics to inform cancer diagnosis and treatment
Rodriguez, H., Zenklusen, J. C., Staudt, L. M., Doroshow, J. H., & Lowy, D. R. (2021) · Cell · doi:10.1016/j.cell.2021.02.055 · Cited by 189
Caruso, S., Calatayud, A.-L., Pilet, J., La Bella, T., Rekik, S., Imbeaud, S., Letouzé, E., Meunier, L., Bayard, Q., Rohr-Udilova, N., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.05.001 · Cited by 186
PROTAC-mediated degradation reveals a non-catalytic function of AURORA-A kinase
Adhikari, B., Bozilovic, J., Diebold, M., Schwarz, J. D., Hofstetter, J., Schröder, M., Wanior, M., Narain, A., Vogt, M., Dudvarski Stankovic, N., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-00652-y · Cited by 171
Murai, H., Kodama, T., Maesaka, K., Tange, S., Motooka, D., Suzuki, Y., Shigematsu, Y., Inamura, K., Mise, Y., Saiura, A., et al. (2023) · Hepatology · doi:10.1002/hep.32573 · Cited by 168
Integrative proteogenomic characterization of hepatocellular carcinoma across etiologies and stages
Ng, C. K. Y., Dazert, E., Boldanova, T., Coto-Llerena, M., Nuciforo, S., Ercan, C., Suslov, A., Meier, M.-A., Bock, T., Schmidt, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29960-8 · Cited by 165
Antibody drug conjugates: lessons from 20 years of clinical experience
Tolcher, A. W. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw424 · Cited by 165
mRNA cancer vaccines: Advances, trends and challenges
He, Q., Gao, H., Tan, D., Zhang, H., & Wang, J.-Z. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.03.011 · Cited by 165
Ang, C., Klempner, S. J., Ali, S. M., Madison, R., Ross, J. S., Severson, E. A., Fabrizio, D., Goodman, A., Kurzrock, R., Suh, J., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.26998 · Cited by 163
Role of liver biopsy in hepatocellular carcinoma
Tommaso, L. D., Spadaccini, M., Donadon, M., Personeni, N., Elamin, A., Aghemo, A., & Lleò, A. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i40.6041 · Cited by 162
Volinsky-Fremond, S., Andani, S., Wolf, J. B., Dijkstra, J., Melsbach, S., Jobsen, J. J., Brinkhuis, M., Roothaan, S. M., Jurgenliemk-Schulz, I. M., Lutgens, L. C. H. W., et al. (2022) · The Lancet Digital Health · doi:10.1016/s2589-7500(22)00210-2 · Cited by 161
Barriers to immune cell infiltration in tumors
Melssen, M. M., Sheybani, N. D., Leick, K. M., & Slingluff, C. L. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006401 · Cited by 159
Pharmaco-proteogenomic characterization of liver cancer organoids for precision oncology
Ji, S., Li, F., Fu, Z., Wu, G., Wu, Y. C., Lin, Y., Lu, D., Song, Y., Cui, P., Yang, Z., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adg3358 · Cited by 156
Self-citationZeng, Q., Klein, C., Caruso, S., Maille, P., Allende, D. S., Mínguez, B., Iavarone, M. A., Ningarhari, M., Casadei-Gardini, A., Pedica, F., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00468-0 · Cited by 156
Vogel, A., Qin, S., Kudo, M., Su, Y., Hudgens, S. A., Yamashita, T., Yoon, J., Fartoux, L., Simon, K. A., López, C., et al. (2021) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(21)00110-2 · Cited by 155
Jackson, R., Psarelli, E., Berhane, S., Khan, H., & Johnson, P. J. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.5197 · Cited by 153
Wang, F., Qin, S., Sun, X., Ren, Z., Meng, Z., Chen, Z., Chai, X., Xiong, J., Bai, Y., Yang, L., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00886-2 · Cited by 149
Désert, R., Rohart, F., Canal, F., Sicard, M., Desille, M., Renaud, S., Turlin, B., Bellaud, P., Perret, C., Clément, B., et al. (2017) · Hepatology · doi:10.1002/hep.29254 · Cited by 148
Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma
Haber, P. K., Castet, F., Torres-Martin, M., Andreu-Oller, C., Puigvehí, M., Miho, M., Radu, P., Dufour, J.-F., Verslype, C., Zimpel, C., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2022.09.005 · Cited by 145
Zhao, Y., Li, Z., Zhu, Y., Fu, J., Zhao, X., Zhang, Y., Wang, S., Wu, J., Wang, K., Wu, R. T., et al. (2021) · Advanced Science · doi:10.1002/advs.202003897 · Cited by 143
Hong, J. Y., Cho, H. J., Sa, J. K., Liu, X., Ha, S. Y., Lee, T., Kim, H., Kang, W., Sinn, D. H., Gwak, G., et al. (2022) · Genome Medicine · doi:10.1186/s13073-021-00995-8 · Cited by 142
Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy
Thomas, A. M., Fidelle, M., Routy, B., Kroemer, G., Wargo, J. A., Segata, N., & Zitvogel, L. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00785-8 · Cited by 141
Zhang, S., Yuan, L., Danilova, L., Mo, G., Zhu, Q., Deshpande, A., Bell, A. T. F., Elisseeff, J., Popel, A. S., Anders, R. A., et al. (2023) · Genome Medicine · doi:10.1186/s13073-023-01218-y · Cited by 140
Self-citationChuah, S., Lee, J. J. X., Song, Y., Kim, H., Wasser, M., Kaya, N. A., Bang, K., Lee, Y. J., Jeon, S. H., Suthen, S., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.03.039 · Cited by 137
Hu, C., & Dignam, J. J. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00086 · Cited by 135
Glypican‐3‐Specific Antibody Drug Conjugates Targeting Hepatocellular Carcinoma
Fu, Y., Urban, D. J., Nani, R. R., Zhang, Y., Li, N., Fu, H., Shah, H., Gorka, A. P., Guha, R., Chen, L., et al. (2018) · Hepatology · doi:10.1002/hep.30326 · Cited by 134
Molecular classification of hepatocellular carcinoma: potential therapeutic implications
Goossens, N., Sun, X., & Hoshida, Y. (2015) · Hepatic Oncology · doi:10.2217/hep.15.26 · Cited by 130
Meng, Y., Ye, F., Nie, P., Zhao, Q., An, L., Wang, W., Qu, S., Shen, Z., Cao, Z., Zhang, X., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.08.024 · Cited by 130
Gao, Q., Wang, Z.-C., Duan, M., Lin, Y.-H., Zhou, X., Worthley, D. L., Wang, X.-Y., Niu, G., Xia, Y., Deng, M., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.09.008 · Cited by 129
Self-citationPROTAC’ing oncoproteins: targeted protein degradation for cancer therapy
Kelm, J. M., Pandey, D. S., Malin, E., Kansou, H. W., Arora, S., Kumar, R., & Gavande, N. S. (2023) · Molecular Cancer · doi:10.1186/s12943-022-01707-5 · Cited by 127
Functional precision oncology using patient-derived assays: bridging genotype and phenotype
van Renterghem, A. W. J., van de Haar, J., & Voest, E. E. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00745-2 · Cited by 124
Zhu, A. X., Dayyani, F., Yen, C., Ren, Z., Bai, Y., Meng, Z., Pan, H., Dillon, P., Mhatre, S. K., Gaillard, V. E., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3275 · Cited by 123
Self-citationSingle-cell analyses identify circulating anti-tumor CD8 T cells and markers for their enrichment
Pauken, K. E., Shahid, O., Lagattuta, K. A., Mahuron, K. M., Luber, J. M., Lowe, M. M., Huang, L., Delaney, C., Long, J. M., Fung, M. E., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20200920 · Cited by 121
Cheng, N., Ren, Y., Zhou, J., Zhang, Y., Wang, D., Zhang, X., Chen, B., Liu, F., Lv, J., Cao, Q., et al. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.02.025 · Cited by 121
A reference cell tree will serve science better than a reference cell atlas
Domcke, S., & Shendure, J. (2023) · Cell · doi:10.1016/j.cell.2023.02.016 · Cited by 121
Li, B., Li, Y., Zhou, H., Xu, Y., Cao, Y., Cheng, C., Peng, J., Li, H., Zhang, L., Su, K., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000553 · Cited by 119
Integrated Multi-Omics Landscape of Liver Metastases
Yang, S., Qian, L., Li, Z., Li, Y., Bai, J., Zheng, B. J., Chen, K., Qiu, X., Cai, G., Wang, S., et al. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.11.029 · Cited by 118
Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma
Hatlen, M. A., Schmidt‐Kittler, O., Sherwin, C. A., Rozsahegyi, E., Rubin, N. T., Sheets, M. P., Kim, J. L., Miduturu, C. V., Bifulco, N., Brooijmans, N., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0367 · Cited by 116
Effects of immune‐related adverse events ( irAEs ) and their treatment on antitumor immune responses
Blum, S. M., Rouhani, S. J., & Sullivan, R. J. (2023) · Immunological Reviews · doi:10.1111/imr.13262 · Cited by 115
Sheng, J., Zhang, J., Wang, L., Tano, V., Tang, J., Wang, X., Wu, J., Song, J., Zhao, Y., Rong, J., et al. (2021) · Gut · doi:10.1136/gutjnl-2021-324339 · Cited by 111
Li, M., Wang, L., Cong, L., Wong, C. C., Zhang, X., Chen, H., Zeng, T., Li, B., Jia, X., Huo, J., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000591 · Cited by 107
Hoes, L. R., Henegouwen, J. M. V. B., van der Wijngaart, H., Zeverijn, L. J., Velden, D. L. V. D., van de Haar, J., Roepman, P., de Leng, W. W. J., Jansen, A. M. L., van Werkhoven, E. D., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3752 · Cited by 106
Huang, X., Hu, M., Sun, T., Li, J., Zhou, Y., Yan, Y., Xuan, B., Wang, J., Xiong, H., Ji, L., et al. (2023) · Cell Host & Microbe · doi:10.1016/j.chom.2023.10.005 · Cited by 102
Predicting breast cancer types on and beyond molecular level in a multi-modal fashion
Zhang, T., Tan, T., Han, L., Appelman, L., Veltman, J., Wessels, R., Duvivier, K. M., Loo, C. E., Gao, Y., Wang, X., et al. (2023) · npj Breast Cancer · doi:10.1038/s41523-023-00517-2 · Cited by 100
Wang, C., Jin, H., Gao, D., Lieftink, C., Evers, B., Jin, G., Zheng, X., Wang, L., Beijersbergen, R. L., Qin, W., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.07.004 · Cited by 99
Self-citationHepatocellular Carcinoma — Origins and Outcomes
Kelley, R. K., & Greten, T. F. (2021) · New England Journal of Medicine · doi:10.1056/nejmcibr2106594 · Cited by 95
Dickkopf-1: A Promising Target for Cancer Immunotherapy
Chu, H. Y., Chen, Z., Wang, L., Zhang, Z., Tan, X., Liu, S., Zhang, B., Lü, A., Yu, Y., & Zhang, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.658097 · Cited by 90
Hatanaka, T., Kakizaki, S., Hiraoka, A., Tada, T., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., et al. (2022) · Hepatology International · doi:10.1007/s12072-022-10358-z · Cited by 90
Kelley, R. K., Meyer, T., Rimassa, L., Merle, P., Park, J., Yau, T. C. C., Chan, S. L., Blanc, J., Tam, V. C., Tran, A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3884 · Cited by 86
Kong, F.-E., Li, G., Tang, Y.-Q., Xi, S., Loong, J. H. C., Li, M., Li, H., Cheng, W., Zhu, W., Mo, J.-Q., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb6282 · Cited by 85
Revolutionizing Precision Oncology through Collaborative Proteogenomics and Data Sharing
Rodriguez, H., & Pennington, S. R. (2018) · Cell · doi:10.1016/j.cell.2018.04.008 · Cited by 81
Finn, R. S., Kudo, M., Cheng, A., Wyrwicz, L. S., Ngan, R. K. C., Blanc, J., Baron, A. D., Vogel, A., Ikeda, M., Piscaglia, F., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4219 · Cited by 81
Molecular and immune landscape of hepatocellular carcinoma to guide therapeutic decision-making
Dhanasekaran, R., Suzuki, H., Lemaitre, L., Kubota, N., & Hoshida, Y. (2023) · Hepatology · doi:10.1097/hep.0000000000000513 · Cited by 81
Spahn, S., Roessler, D., Pompilia, R., Gabernet, G., Gladstone, B. P., Horger, M., Biskup, S., Feldhahn, M., Nahnsen, S., Hilke, F. J., et al. (2020) · Cancers · doi:10.3390/cancers12123830 · Cited by 79
ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma
Myojin, Y., Kodama, T., Maesaka, K., Motooka, D., Sato, Y., Tanaka, S., Abe, Y., Ohkawa, K., Mita, E., Hayashi, Y., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3382 · Cited by 75
Transitioning single-cell genomics into the clinic
Lim, J. W. Y., Chin, V. T., Fairfax, K. A., Moutinho, C., Suan, D., Ji, H. P., & Powell, J. E. (2023) · Nature Reviews Genetics · doi:10.1038/s41576-023-00613-w · Cited by 74
Hou, X., Du, C., Lu, L., Yuan, S., Zhan, M., You, P., & Du, H. (2022) · World Journal of Surgical Oncology · doi:10.1186/s12957-022-02510-8 · Cited by 73
Cartry, J., Bedja, S., Boilève, A., Mathieu, J. R. R., Gontran, E., Annereau, M., Job, B., Mouawia, A., Mathias, P., de Baère, T., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02853-4 · Cited by 73
Tsuchiya, K., Asahina, Y., Matsuda, S., Muraoka, M., Nakata, T., Suzuki, Y., Tamaki, N., Yasui, Y., Suzuki, S., Hosokawa, T., et al. (2013) · Cancer · doi:10.1002/cncr.28384 · Cited by 64
Leung, C. O. N., Yang, Y., Leung, R. W. H., So, K. K. H., Guo, H. J., Lei, M. M. L., Muliawan, G. K., Gao, Y., Yu, Q. Q., Yun, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42360-w · Cited by 64
Yang, Y., Wen, F., Li, J., Zhang, P., Yan, W., Hao, P., Xia, F., Bi, F., & Li, Q. (2015) · Liver International · doi:10.1111/liv.12805 · Cited by 63
Chuma, M., Uojima, H., Numata, K., Hidaka, H., Toyoda, H., Hiraoka, A., Tada, T., Hirose, S., Atsukawa, M., Itokawa, N., et al. (2020) · Cancers · doi:10.3390/cancers12020293 · Cited by 58
Limousin, W., Laurent‐Puig, P., Ziol, M., Ganne‐Carrié, N., Nahon, P., Ait-Omar, A., Séror, O., Sidali, S., Campani, C., Blanc, P., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.08.017 · Cited by 55
Campani, C., Bamba‐Funck, J., Campion, B., Sidali, S., Blaise, L., Ganne‐Carrié, N., Demory, A., Sutter, O., Larrey, E., Evain, M., et al. (2022) · Liver International · doi:10.1111/liv.15487 · Cited by 51
Yang, C. G., Zhang, S., Cheng, Z., Liu, Z., Zhang, L., Jiang, K., Geng, H., Qian, R., Wang, J., Huang, X., et al. (2022) · Genome Medicine · doi:10.1186/s13073-022-01143-6 · Cited by 50
Self-citationZhu, H., Lin, Y., Lu, D., Wang, S., Liu, Y., Dong, L., Meng, Q., Gao, J., Wang, Y., Song, N., et al. (2023) · National Science Review · doi:10.1093/nsr/nwad167 · Cited by 50
Self-citationBiopsy for advanced hepatocellular carcinoma: results of a multicentre UK audit
Childs, A., Zakeri, N., Ma, Y. T., O’Rourke, J. M., Ross, P. J., Hashem, E., Hubner, R. A., Hockenhull, K., Iwuji, C., Khan, S., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01535-2 · Cited by 48
In vitro modeling of hepatocellular carcinoma molecular subtypes for anti-cancer drug assessment
Hirschfield, H., Bian, C. B., Higashi, T., Nakagawa, S., Zeleke, T. Z., Nair, V. D., Fuchs, B. C., & Hoshida, Y. (2018) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.164 · Cited by 47
The application of patient-derived organoid in the research of lung cancer
Li, Y., Gao, X., Ni, C., Zhao, B. T., & Cheng, X. (2023) · Cellular Oncology · doi:10.1007/s13402-023-00771-3 · Cited by 45
Targeting BET Proteins With a PROTAC Molecule Elicits Potent Anticancer Activity in HCC Cells
Zhang, H., Li, G., Zhang, Y., Shi, J., Yan, B., Tang, H., Chen, S., Zhang, J., Wen, P., Wang, Z., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01471 · Cited by 44
Self-citationThe proteomic characterization of the peritumor microenvironment in human hepatocellular carcinoma
Gu, Y., Guo, Y., Gao, N., Fang, Y., Xu, C., Hu, G., Guo, M., Ma, Y., Zhang, Y., Zhou, J., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02264-3 · Cited by 43
Schmidt, B. H., Wei, L., DePeralta, D. K., Hoshida, Y., Tan, P. S., Sun, X., Sventek, J. P., Lanuti, M. D., Tanabe, K. K., & Fuchs, B. C. (2015) · International Journal of Cancer · doi:10.1002/ijc.29893 · Cited by 38
Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma
Muhammed, A., D’Alessio, A., Enica, A., TALBOT, T. L., Fulgenzi, C. A. M., Nteliopoulos, G., Goldin, R. D., Cortellini, A., & Pinato, D. J. (2022) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2022.2049244 · Cited by 38
Yukimoto, A., Hirooka, M., Hiraoka, A., Michitaka, K., Ochi, H., Joko, K., Imai, Y., Watanabe, T., Koizumi, Y., Yoshida, O., et al. (2018) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyy153 · Cited by 35
Yang, C. G., Chen, J., Li, Y., Huang, X., Liu, Z., Wang, J., Jiang, H., Qin, W., Lv, Y., Wang, H., et al. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa295 · Cited by 32
Self-citationMapping the Landscape of Synthetic Lethal Interactions in Liver Cancer
Chen, Y., Guo, Y., Qian, R., Huang, Y., Zhang, L., Wang, J., Huang, X., Liu, Z., Qin, W., Wang, C., et al. (2021) · Theranostics · doi:10.7150/thno.63416 · Cited by 31
Self-citationCirculating tumour cell isolation, analysis and clinical application
Zhang, X., Xie, P., Zhang, K., & Zhang, W. (2023) · Cellular Oncology · doi:10.1007/s13402-023-00774-0 · Cited by 30
Vithayathil, M. K., D’Alessio, A., Fulgenzi, C. A. M., Nishida, N., Schönlein, M., von Felden, J., Schulze, K., Wege, H., Saeed, A., Wietharn, B., et al. (2023) · Hepatology International · doi:10.1007/s12072-023-10491-3 · Cited by 28
Howell, J. A., Samani, A., Mannan, B., Hajiev, S., Aval, L. M., Abdelmalak, R., Tam, V. C., Bettinger, D., Thimme, R., Taddei, T. H., et al. (2022) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848221100106 · Cited by 22
Deng, Y., Yu, C., Chen, L., Zhang, X., Lei, Q., Liu, Q., Cai, G., & Liu, F. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.858901 · Cited by 20
Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma
Tomonari, T., Sato, Y., Tanaka, H., Mitsuhashi, T., Hirao, A., Tanaka, T., Taniguchi, T., Okamoto, K., Sogabe, M., Miyamoto, H., et al. (2021) · JGH Open · doi:10.1002/jgh3.12663 · Cited by 17
Hayashi, T., Shibata, M., Oe, S., Miyagawa, K., Honma, Y., & Harada, M. (2020) · PLoS ONE · doi:10.1371/journal.pone.0244370 · Cited by 16
Cellsnake: a user-friendly tool for single-cell RNA sequencing analysis
Umu, S. U., Vander-Elst, K. R., Karlsen, V. T., Chouliara, M., Bækkevold, E. S., Jahnsen, F. L., & Domańska, D. (2022) · GigaScience · doi:10.1093/gigascience/giad091 · Cited by 14
Genomic profiling of cell lines for personalized targeted therapy for hepatocellular carcinoma
Deshmukh, M., & Hoshida, Y. (2013) · Hepatology · doi:10.1002/hep.26407 · Cited by 12
Liao, H., Du, J., Wang, H., Lan, T., Peng, J., Wu, Z., Yuan, K., & Zeng, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01195-y · Cited by 11
Obesity and non-alcoholic steatohepatitis in immunotherapy for hepatocellular carcinoma
Shiina, S., Maruyama, H., Tobari, M., & Yamashita, T. (2023) · Hepatology International · doi:10.1007/s12072-023-10533-w · Cited by 4
Unlocking the immune microenvironment of nonalcoholic steatohepatitis-associated HCC
Ma, S., & Chew, V. (2023) · Hepatology · doi:10.1097/hep.0000000000000626 · Cited by 4
Metadata
- Authors
- Yang, X., Yang, C., Zhang, S., Geng, H., Zhu, A. X., Bernards, R., Qin, W., Fan, J., Wang, C., & Gao, Q.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2024-02
- Volume
- 42
- Issue
- 2
- Pages
- 180-197
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W4391743535
- Cited by
- 429
- References
- 183
- FWCI
- 96.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.